Newco News Novelty Nobility attracts $9M in series A funding for NN2101 GLP tox studies Feb. 4, 2020 By Jihyun Kim No Comments HONG KONG – South Korean biotech Novelty Nobility Inc. has attracted ₩10 billion (US$9 million) in series A funding to develop therapeutic antibodies inhibiting the stem cell factor (SCF)/c-KIT pathway.Read More